BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Princess Margaret Hospital
Christchurch, Nueva ZelandaPrincess Margaret Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477